With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.
Biomarker-Targeted Therapy in 2025: Precise Patient Selection, MRD, Antibody-Drug Conjugates
Premium
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
The FDA approved three new gene therapy products in 2024 and expanded indications for two others, all for rare diseases.
Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon established CAR T-cell therapies.
AI-driven tools for prescreening patients, predicting responses and outcomes, and guiding patient therapy are maturing and entering the market.